business.financialpost.com
Pharma exec Martin Shkreli may be an ass, but he’s only taking advantage of warped U.S. regulatory incentives
Apparently unwilling to have certain drugs out of regulatory compliance, even long-proven medicines, the FDA has been offering an incentive to put such compounds under its influence